MASH

News

Already sitting on a blockbuster therapy for MASH, Madrigal has beefed up its pipeline with six siRNA candidates licensed from China's Ribo.

News

Madrigal Pharma is reheating a drug for metabolic dysfunction-associated steatohepatitis (MASH) put on ice by Pfizer last year.

News

The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with MASH to help measure disease activity.

News

Novo Nordisk has agreed to buy Akero and its MASH drug efruxifermin for $4.7bn upfront, soon after Wegovy was approved for the common liver disease.

News

Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and its phase 3 candidate pegozafermin for MASH.

News

Under pressure from rivals in the GLP-1 space, Novo Nordisk has been given a leg-up with a first-in-class approval for Wegovy in liver disease MASH.